Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 2.13B -60.5% |
| Revenue (ttm) | 2.20B +15.6% |
| Net Income | -713.41M |
| EPS | -7.13 |
| Shares Out | 104.99M |
| PE Ratio | n/a |
| Forward PE | 6.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,076,721 |
| Open | 20.65 |
| Previous Close | 20.42 |
| Day's Range | 19.93 - 20.68 |
| 52-Week Range | 10.42 - 64.80 |
| Beta | 0.28 |
| Analysts | Hold |
| Price Target | 25.85 (+27.34%) |
| Earnings Date | May 6, 2026 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $25.85, which is an increase of 27.34% from the latest price.
News
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasd...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously ap...
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) ...
Sarepta Therapeutics Transcript: Study result
Preliminary phase I/II data for SRP-1001 (FSHD) and SRP-1003 (DM1) show robust, dose-dependent muscle delivery, strong gene knockdown, and favorable safety profiles. Both programs plan to advance to phase III in 2027, with more MAD data expected later this year.
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA p...
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Easter...
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
The stock's decline comes as the company plans to submit supplemental new drug applications to the U.S. Food and Drug Administration (FDA) by the end of April, as detailed in the regulatory update.
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions...
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort...
Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Revenue guidance for 2026 remains strong, with ELEVIDYS and PMO franchises supported by robust clinical data and ongoing sales force expansion. Key clinical milestones for DM1, FSHD, and nonambulant ELEVIDYS are on track, while pivotal trials and manufacturing scale-up are targeted for 2027.
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne ...
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinic...
Sarepta CEO To Jump Ship After 'Tumultuous' Year
On Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million...
Sarepta Therapeutics CEO Ingram to retire by year end
Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
Sarepta Therapeutics Earnings Call Transcript: Q4 2025
Entered 2026 with strong financials, $2.2B 2025 revenue, and $954M cash. ELEVIDYS and PMO franchises remain stable, with new educational initiatives expected to drive 2026 revenue of $1.2–$1.4B. CEO to retire by end of 2026; robust pipeline and Japan launch support future growth.
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful...
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene mo...
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results...
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Med...
Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys
Sarepta reports positive, statistically significant results in a study evaluating the efficacy of its blockbuster gene therapy.
Sarepta Therapeutics Transcript: Study result
Three-year results from the EMBARK Phase 3 trial show ELEVIDYS provides sustained, statistically significant slowing of Duchenne progression, with treated patients maintaining motor function and experiencing fewer losses of ambulation compared to controls. No new safety signals emerged, and benefits appear to widen over time.
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
Sarepta Therapeutics' gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a late‑...
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results ...
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Easte...